171 related articles for article (PubMed ID: 21822504)
1. Intrinsic disorder in the androgen receptor: identification, characterisation and drugability.
McEwan IJ
Mol Biosyst; 2012 Jan; 8(1):82-90. PubMed ID: 21822504
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding.
Lavery DN; McEwan IJ
Biochemistry; 2008 Mar; 47(11):3360-9. PubMed ID: 18284208
[TBL] [Abstract][Full Text] [Related]
3. Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.
Sadar MD
Expert Opin Drug Discov; 2020 May; 15(5):551-560. PubMed ID: 32100577
[No Abstract] [Full Text] [Related]
4. Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.
Kuznik NC; Solozobova V; Jung N; Gräßle S; Lei Q; Lewandowski EM; Munuganti R; Zoubeidi A; Chen Y; Bräse S; Cato ACB
ACS Chem Biol; 2021 Nov; 16(11):2103-2108. PubMed ID: 34506104
[TBL] [Abstract][Full Text] [Related]
5. The human androgen receptor AF1 transactivation domain: interactions with transcription factor IIF and molten-globule-like structural characteristics.
Lavery DN; McEwan IJ
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1054-7. PubMed ID: 17073749
[TBL] [Abstract][Full Text] [Related]
6. An androgen receptor N-terminal domain antagonist for treating prostate cancer.
Myung JK; Banuelos CA; Fernandez JG; Mawji NR; Wang J; Tien AH; Yang YC; Tavakoli I; Haile S; Watt K; McEwan IJ; Plymate S; Andersen RJ; Sadar MD
J Clin Invest; 2013 Jul; 123(7):2948-60. PubMed ID: 23722902
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of the native NH2-terminal transactivation domain of the human androgen receptor: binding kinetics for interactions with TFIIF and SRC-1a.
Lavery DN; McEwan IJ
Biochemistry; 2008 Mar; 47(11):3352-9. PubMed ID: 18284209
[TBL] [Abstract][Full Text] [Related]
8. Topological dynamics of an intrinsically disordered N-terminal domain of the human androgen receptor.
Sheikhhassani V; Scalvini B; Ng J; Heling LWHJ; Ayache Y; Evers TMJ; Estébanez-Perpiñá E; McEwan IJ; Mashaghi A
Protein Sci; 2022 Jun; 31(6):e4334. PubMed ID: 35634773
[TBL] [Abstract][Full Text] [Related]
9. A sting in the tail: the N-terminal domain of the androgen receptor as a drug target.
Monaghan AE; McEwan IJ
Asian J Androl; 2016; 18(5):687-94. PubMed ID: 27212126
[TBL] [Abstract][Full Text] [Related]
10. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
11. Promoter-dependent activity on androgen receptor N-terminal domain mutations in androgen insensitivity syndrome.
Tadokoro-Cuccaro R; Davies J; Mongan NP; Bunch T; Brown RS; Audi L; Watt K; McEwan IJ; Hughes IA
Sex Dev; 2014; 8(6):339-49. PubMed ID: 25500996
[TBL] [Abstract][Full Text] [Related]
12. Backbone 1H, 15N, 13C NMR assignment of the 518-627 fragment of the androgen receptor encompassing N-terminal and DNA binding domains.
Meyer S; Wang YH; Pérez-Escrivà P; Kieffer B
Biomol NMR Assign; 2016 Apr; 10(1):175-8. PubMed ID: 26732902
[TBL] [Abstract][Full Text] [Related]
13. N-terminal domain of the androgen receptor contains a region that can promote cytoplasmic localization.
Dar JA; Eisermann K; Masoodi KZ; Ai J; Wang D; Severance T; Sampath-Kumar SD; Wang Z
J Steroid Biochem Mol Biol; 2014 Jan; 139():16-24. PubMed ID: 24099702
[TBL] [Abstract][Full Text] [Related]
14. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity.
Sadar MD
Cancer Res; 2011 Feb; 71(4):1208-13. PubMed ID: 21285252
[TBL] [Abstract][Full Text] [Related]
16. In vitro regulation of reporter gene transcription by the androgen receptor AF1 domain.
Choudhry MA; McEwan IJ
Biochem Soc Trans; 2004 Dec; 32(Pt 6):1103-6. PubMed ID: 15506979
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
18. Peptide antagonist of the androgen receptor.
Gao W
Curr Pharm Des; 2010; 16(9):1106-13. PubMed ID: 20030610
[TBL] [Abstract][Full Text] [Related]
19. Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding.
Brodie J; McEwan IJ
J Mol Endocrinol; 2005 Jun; 34(3):603-15. PubMed ID: 15956332
[TBL] [Abstract][Full Text] [Related]
20. Characterization of niphatenones that inhibit androgen receptor N-terminal domain.
Banuelos CA; Lal A; Tien AH; Shah N; Yang YC; Mawji NR; Meimetis LG; Park J; Kunzhong J; Andersen RJ; Sadar MD
PLoS One; 2014; 9(9):e107991. PubMed ID: 25268119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
